Seaport Therapeutics, Inc. Common Stock (SPTX) Stock Score, Valuation & Financial Research

Seaport Therapeutics, Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SPTX

Seaport Therapeutics, Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 19.61. These figures are a research snapshot, not a buy or sell recommendation.

What Seaport Therapeutics, Inc. Common Stock does

Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Seaport Therapeutics is a clinical-stage biotechnology company that does not currently generate commercial revenue. Its business model relies on research and development of neuropsychiatric medicines using its proprietary Glyph Platform, with future revenue dependent on the successful development, regulatory approval, and commercialization of its product candidates.

Products and services

  • The company is developing novel therapeutics for depression, anxiety, and other neuropsychiatric disorders using its proprietary Glyph Platform, which is designed to improve the oral bioavailability of drugs.

Suppliers, materials and equipment

  • Contract Research Organizations — The company engages various unnamed third-party contract research organizations to conduct clinical trials and research activities. Source

Business relationships and partnerships

  • Monash University — A research collaboration and license agreement under which Seaport has an exclusive option to license inventions pertaining to prodrug technology and collaborates on research and development activities. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — The company operates in a highly competitive environment facing numerous pharmaceutical and biotechnology companies developing treatments for neuropsychiatric disorders. Source

Business strengths to evaluate

  • Proprietary Glyph Platform technology Source

Business risks and research considerations

  • History of operating losses and no history of commercial revenue Source
  • Uncertainty regarding successful development and commercialization of product candidates Source

Sources: Company research source · Pharmaceutical and biotechnology companies

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SPTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 19.61
Market capitalization:
1.05B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -74.88M
Free cash flow:
USD -78.3M
Cash:
USD 64.22M
Total debt:
USD 5.02M
EPS:
USD -1.94

What stands out

  • Free cash flow is USD -78.3M, negative for the stored period.
  • The balance sheet shows USD 64.22M of cash versus USD 5.02M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 59.21M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SPTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SPTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SPTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SPTX to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of SPTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research SPTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.